TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01222416

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical Administration [18F]-FDG
Description: Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical: [18F]-FLT
Description: Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
Study: NCT03114462

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Hypofractionated Radioablation
Description: Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
Study: NCT00584987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fluticasone furoate
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oxymetazoline
Description: 2 puffs of each nasal spray in each nostril in the pm
Study: NCT00881023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System
Description: A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System
Description: A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
Study: NCT03727776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone
Description: Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
Study: NCT03780088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mTranS-C
Description: mobile health
Study: NCT02906098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient centered oral health education
Description: Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard educational intervention
Description: Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
Study: NCT03567590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency treatment
Description: The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block treatment
Description: A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
Study: NCT00233324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Description: Intubation and administration of surfactant by 1 hour of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Description: Intubation and administration of surfactant by 1 hour of age.
Study: NCT03206918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
Study: NCT02845193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/NAM
Description: computer aided design NAM
Study: NCT04142112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ohana IVF Sperm Preparation Kit (OHB035)
Description: The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IVF Preparation Kit (OHB037)
Description: The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
Study: NCT00815360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab
Study: NCT00233324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
Study: NCT00815360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral laser
Description: ultra-widefield fluorescein angiography guided peripheral laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of triamcinolone acetonide
Description: intravitreal injection of 4.0 mg triamcinolone acetonide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular laser
Description: macular laser to areas of retinal thickening or leakage
Study: NCT02031718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Counseling
Study: NCT00575887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
Study: NCT04035915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited driving pressure
Description: Keep driving pressure \<15 cmH2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional mechanical ventilation strategies
Description: Keep tidalvolume \</= 8
Study: NCT02016703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol drink
Study: NCT04443270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days.
Study: NCT01528488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOZAC Calming Skin Spray
Description: EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
Study: NCT02016703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo drink
Study: NCT01271062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: very low caloric diet
Study: NCT01658072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-Articular Injection
Description: Use of a different analgesic protocol, based on a peri-articular injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Patient Controlled Analgesia (Epidural PCA)
Description: Epidural analgesia pathway.
Study: NCT03013478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment As Usual (TAU)
Description: Treatment normally offered at this primary care clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT4CBT program
Study: NCT01092104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652
Description: TBR-652 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBR-652 Matching Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 50 mg
Description: TBR-652 50 mg QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 75 mg
Description: TBR-652 75 mg QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 100 mg
Description: TBR-652 100 mg QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 150 mg
Description: TBR-652 150 mg QD for 10 days
Study: NCT01709162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT02016703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo drink
Study: NCT01709162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study: NCT00929318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Study: NCT04334694

Intervention type: DEVICE
Group type: OTHER
Intervention: Atrial flow regulator (Occlutech® AFR device)
Description: Atrial septostomy followed by implantation of AFR.
Study: NCT03122288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Cognitive Training
Description: These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).

Intervention type: OTHER
Group type: OTHER
Intervention: No-Contact Control
Description: This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
Study: NCT00447993

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Dose NT-501
Description: Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High Dose NT-501
Description: High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
Study: NCT04292665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Exercise
Description: During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will continue to receive standard nursing care and no further intervention will be made during the research.
Study: NCT02546466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Star-shape taping (SFT)
Description: For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Functional Taping (Sham-FT)
Description: For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Strategy (MIS)
Description: The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
Study: NCT02111928

Intervention type: DEVICE
Intervention: NovaTears® Eye Drops
Description: Topical eye drops for lubrication of the ocular surface
Study: NCT01269333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole 20mg for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine
Description: fluvoxamine 50mg for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 7 days
Study: NCT04201886

Intervention type: OTHER
Group type: OTHER
Intervention: serum calprotectin
Description: serum calcium binding leucocyte protein

Intervention type: OTHER
Group type: OTHER
Intervention: serum calprotectin
Description: serum calcium binding leucocyte protein
Study: NCT02476240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkinson's disease Sensory Attention Focused Exercise
Description: The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkinson's disease Sensory Attention Focused Exercise
Description: The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
Study: NCT02249130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T)
Study: NCT02702661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB)
Description: Fascia Iliaca Compartment Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic Infiltration (LAI)
Description: Local Anaesthetic Infiltration (LAI) of the portal tracts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine 0.125% - 40ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine 0.125% - 40ml
Study: NCT02185053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Study: NCT01464931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Adminstered by subcutaneous injection
Study: NCT03040557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible footwear
Description: - Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthopedic insole
Description: - Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
Study: NCT04708548

Intervention type: OTHER
Intervention: Health-related Quality of Life
Description: Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.

Intervention type: OTHER
Intervention: Psychological Distress
Description: Measured of the distress experienced by patients

Intervention type: OTHER
Intervention: Fatigue
Description: Measure of the extreme tiredness resulting from mental or physical exertion or illness

Intervention type: OTHER
Intervention: Cognitive Functioning
Description: Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
Study: NCT03838510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBOOT
Description: The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
Study: NCT00233324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 85 to 89%
Description: Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 85 to 89%
Description: Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
Study: NCT02475746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Interacting drug which will be given 200 mg QD for 8 days in period 2